Article Link: FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma PARIS and TARRYTOWN, N.Y., Oct. 19, 2018 /PRNewswire/ ̵...
FDA Approves Talzenna (talazoparib) for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer
Article Link: FDA Approves Talzenna (talazoparib) for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer On October 16, 20...
FDA Approves Liletta (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years
Article Link: FDA Approves Liletta (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years DUBLIN ...
FDA Approves Yutiq (fluocinolone acetonide intravitreal implant) for Chronic Non-Infectious Posterior Segment Uveitis
Article Link: FDA Approves Yutiq (fluocinolone acetonide intravitreal implant) for Chronic Non-Infectious Posterior Segment Uveitis WATER...
FDA Approves Xarelto to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
Article Link: FDA Approves Xarelto to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Periphe...
FDA Approves Accelerated 7-Day Vaccine Dosing Schedule for Ixiaro
Article Link: FDA Approves Accelerated 7-Day Vaccine Dosing Schedule for Ixiaro GAITHERSBURG, Md.–(BUSINESS WIRE) October 05, 2018 ...
FDA Approves Tegsedi (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
Article Link: FDA Approves Tegsedi (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis B...
FDA Approves Revcovi (elapegademase-lvlr) for Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID)
Article Link: FDA Approves Revcovi (elapegademase-lvlr) for Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID) GAITHERSBURG...
FDA Approves Expanded Use of Gardasil 9 to Include Individuals 27 Through 45 Years Old
Article Link: FDA Approves Expanded Use of Gardasil 9 to Include Individuals 27 Through 45 Years Old October 5, 2018 — The U.S. Foo...
FDA Approves Genentech’s Hemlibra (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors
Article Link: FDA Approves Genentech’s Hemlibra (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors South San Francisco, CA...
